A 57-year-old man presented with a 1-week history of coughing up blood and darkening of the urine. The patient developed a dry hacking cough 1 month before the current presentation. He denied fever, chills, night sweats, or weight loss. His medical history was significant for rheumatoid arthritis treated with prednisone, 5 mg/d; non-Hodgkin lymphoma, for which he was recently treated with 5 cycles of cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone, and rituximab; hypothyroidism; type 1 diabetes mellitus with insulin therapy; and vitiligo. Vital signs were normal, and physical examination was significant for bilateral dependent pulmonary crackles. Urinalysis showed blood, but no protein, and sediment evaluation showed numerous red blood cells (RBCs) without casts. Blood work identified normocytic anemia and acute kidney injury with a serum creatinine level of 5 mg/dL (442 μmol/L; baseline creatinine, 1.2 mg/dL [106.1 μmol/L]). The patient was started on pulse steroid therapy for a presumed pulmonary-renal syndrome caused by autoimmune vasculitis.
■ What is the differential diagnosis for this presentation?
■ What is the appropriate diagnostic and therapeutic approach in this case, and are there special considerations in immunocompromised patients?
Discussion
What is the differential diagnosis for this presentation?
Our patient presented with a triad of hemoptysis, hematuria, and acute kidney injury. Given his other autoimmune diseases, pulmonary-renal syndrome caused by autoimmune vasculitis was suspected. The term pulmonary-renal syndrome refers to the combination of diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis. Patients may present with severe respiratory and/or kidney failure. A variety of mechanisms, such as those involving anti–glomerular basement membrane antibodies, antineutrophil cytoplasm antibodies, immunocomplexes, and thrombotic microangiopathy, are implicated in the pathogenesis of this syndrome. Because the syndrome is characterized by a fulminant course if left untreated, early diagnosis and timely initiation of treatment are crucial for the patient's outcome. In our patient, pulse steroid therapy was started before confirming an autoimmune process.
What is the appropriate diagnostic and therapeutic approach in this case, and are there special considerations in immunocompromised patients?
In a patient with clinical suspicion for pulmonary-renal syndrome, the presence of glomerulonephritis and pulmonary hemorrhage should be confirmed, ideally with bronchoscopy and evidence of RBC casts in the urine sediment, while awaiting results of a kidney biopsy. In our patient, chest x-ray and computed tomographic scan showed a cavitary consolidation of the left upper lung lobe (Fig 1), and urine sediment showed numerous RBCs without casts. These findings are not consistent with the diagnosis of pulmonary-renal syndrome and suggested other causes of lung and kidney disease. Results of additional workup, including antinuclear antibody, antineutrophil cytoplasmic antibody, prothrombin time, partial thromboplastin time, hepatitis panel, human immunodeficiency virus antibodies, anti–glomerular basement membrane antibodies, ASO, complement titers, erythrocyte sedimentation rate, C-reactive protein, sputum smears for acid-fast bacilli (AFB), purified protein derivative (tuberculin) testing, and assays Mycobacterium tuberculosis infection (QuantiFERON; Cellestis Limited, Carnegie, Australia), Aspergillus antibodies, and Cryptococcus antigen were all within normal limits. The kidney biopsy showed invasive fungal infection consistent with zygomycosis, infarction secondary to arterial fungal thrombosis, and ATN (Fig 2). Steroid therapy was stopped, and the patient was started on liposomal amphotericin B. Fungal culture results grew Rhizopus species. The patient required dialysis and died shortly afterward.